Clinical outcomes of ceftazidime-avibactam versus meropenem in Indian patients with nosocomial pneumonia: Subset analysis from the REPROVE study
Authors:
Open Access
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 39 (3) , 363-366
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
This publication has 11 references indexed in Scilit:
- Colistin-Sparing Approaches with Newer Antimicrobials to Treat Carbapenem-Resistant Organisms: Current Evidence and Future ProspectsIndian Journal of Medical Microbiology, 2019
- Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2018
- Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy VolunteersDrugs in R&D, 2018
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial InfectionsDrugs, 2018
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trialThe Lancet Infectious Diseases, 2018
- Bacteriological profile of ventilator-associated pneumonia in a tertiary care hospitalIndian Journal of Pathology and Microbiology, 2018
- Epidemiology and characteristics of nosocomial infections in critically ill patients in a tertiary care Intensive Care Unit of Northern IndiaSaudi Journal of Anaesthesia, 2017
- Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant EnterobacteriaceaeClinical Infectious Diseases, 2017
- Emerging trends of nosocomial pneumonia in intensive care unit of a tertiary care public teaching hospital in Western IndiaAnnals of African Medicine, 2017
- Intensive care unit bugs in India: How do they differ from the Western world?The Journal of Association of Chest Physicians, 2017